ACLA Evaluating CMS’ Final National Coverage Determination on Next Generation Sequencing
(Washington, D.C.) – The American Clinical Laboratory Association (ACLA) stated that it is reviewing the Centers for Medicare & Medicaid Services (CMS) final National Coverage Determination (NCD) released today on Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer. The association had previously voiced concerns in response to the proposed NCD, cautioning that it would deprive Medicare beneficiaries of access to critical laboratory testing, which is a key part of precision medicine.
“ACLA is evaluating CMS’ final NCD released today on Next Generation Sequencing for Medicare Beneficiaries with Advanced Cancer,” said Julie Khani, president of the ACLA. “We recognize that CMS has made significant changes from the draft NCD as a result of the concerns expressed by many stakeholders. We are evaluating the final NCD with our members, and will determine how it aligns with ACLA’s goals of maintaining access to laboratory testing for Medicare beneficiaries, and spurring continued innovation in this cutting-edge and clinically impactful testing.”
To view ACLA’s previously issued comments on CMS’ draft NCD click here.
# # #
ACLA is a not-for-profit association representing the nation’s leading clinical and anatomic pathology laboratories, including national, regional, specialty, ESRD, hospital and nursing home laboratories. The clinical laboratory industry employs nearly 277,000 people directly and generates over 115,000 additional jobs in supplier industries. Clinical laboratories are at the forefront of personalized medicine, driving diagnostic innovation and contributing more than $100 billion to the nation’s economy.
